| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/03/2013 | EP2609933A1 Aqueous composition for ophthalmic administration |
| 07/03/2013 | EP2609929A1 Composition for preventing or treating dementia |
| 07/03/2013 | EP2609928A2 Use of cannabinoids in combination with an anti-psychotic medicament |
| 07/03/2013 | EP2609925A2 Dermatan sulfate for use in the treatment of pathologies wherein metalloproteinases are involved |
| 07/03/2013 | EP2609924A1 Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles |
| 07/03/2013 | EP2609923A2 Nucleoside Phosphoramidates |
| 07/03/2013 | EP2609922A1 Pharmaceutical composition for treating chronic liver disease and use thereof |
| 07/03/2013 | EP2609921A1 Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| 07/03/2013 | EP2609920A1 Method of treating cancer by a combined therapy of YM-155 with other anticancer agents |
| 07/03/2013 | EP2609919A2 c-Met modulators and methods of use |
| 07/03/2013 | EP2609918A1 Peritoneal dialysis fluid comprising a GSK-3 inhibitor |
| 07/03/2013 | EP2609917A1 Triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase |
| 07/03/2013 | EP2609916A1 New therapeutic approaches for treating CMT and related disorders |
| 07/03/2013 | EP2609915A1 Dialysis and substitution fluid |
| 07/03/2013 | EP2609914A1 Novel methods for treating or preventing neurodegeneration |
| 07/03/2013 | EP2609912A1 Pharmaceutical combination of fingolimod and nabiximols |
| 07/03/2013 | EP2609812A1 Liquid nucleotides/nucleosides-containing product |
| 07/03/2013 | EP2609199A1 Mir-33 inhibitors and uses thereof |
| 07/03/2013 | EP2609135A2 Poly(beta-amino alcohols), their preparation, and uses thereof |
| 07/03/2013 | EP2609120A1 Improved process for preparation of sugammadex |
| 07/03/2013 | EP2609108A1 Certain chemical entities, compositions, and methods |
| 07/03/2013 | EP2609106A1 RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/03/2013 | EP2609100A2 Furopyridine derivatives |
| 07/03/2013 | EP2609098A1 Triazolopyrazine derivatives |
| 07/03/2013 | EP2609097A1 Pyridyl-amine fused azadecalin modulators |
| 07/03/2013 | EP2609096A1 New tiotropium bromide crystal and its production method |
| 07/03/2013 | EP2609095A2 Compounds that modulate intracellular calcium |
| 07/03/2013 | EP2609093A1 Salt compound |
| 07/03/2013 | EP2609092A1 Oxadiazole inhibitors of leukotriene production |
| 07/03/2013 | EP2609091A1 Pharmaceutically active compounds as axl inhibitors |
| 07/03/2013 | EP2609089A1 Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 07/03/2013 | EP2609087A2 Pure intermediate |
| 07/03/2013 | EP2609086A1 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| 07/03/2013 | EP2609085A1 Substituted quinoline-3-carboxamides as kcnq2/3 modulators |
| 07/03/2013 | EP2609084A1 Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
| 07/03/2013 | EP2609083A1 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
| 07/03/2013 | EP2609082A1 Imidazo[4,5-c]quinolines as dna-pk inhibitors |
| 07/03/2013 | EP2609078A1 Hydroxamate-based inhibitors of deacetylases |
| 07/03/2013 | EP2609064A2 Pharmaceutical compositions comprising poh derivatives |
| 07/03/2013 | EP2608847A1 Theobromine in combination with an expectorant or a mucolytic for use in therapy |
| 07/03/2013 | EP2608812A2 Methods targeting mir-33 micrornas for regulating lipid metabolism |
| 07/03/2013 | EP2608796A2 Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| 07/03/2013 | EP2608795A1 Synergistic fungicidal composition |
| 07/03/2013 | EP2608794A1 Methods and compositions for preventing or treating obesity |
| 07/03/2013 | EP2608793A1 Use of a receptor-type kinase modulator for treating polycystic kidney disease |
| 07/03/2013 | EP2608792A1 Methods of administering an egfr inhibitor |
| 07/03/2013 | EP2608791A1 A process for the preparation of imatinib base |
| 07/03/2013 | EP2608790A1 Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer |
| 07/03/2013 | EP2608789A1 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| 07/03/2013 | EP2608788A1 Polymorphs of saxagliptin hydrochloride and processes for preparing them |
| 07/03/2013 | EP2608787A1 Proline sulfonamide derivatives as orexin receptor antagonists |
| 07/03/2013 | EP2608786A2 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
| 07/03/2013 | EP2608785A2 Lipomacrocycles and uses thereof |
| 07/03/2013 | EP2608784A1 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| 07/03/2013 | EP2608783A1 Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| 07/03/2013 | EP2608782A1 Novel use of leflunomide and malononitrilamides |
| 07/03/2013 | EP2608781A1 Inclusion complexes of cyclodextrins with spermidine, and proliferative/reparative compositions comprising thereof |
| 07/03/2013 | EP2608779A2 Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| 07/03/2013 | EP2608777A2 Compositions and methods for cardiac therapy |
| 07/03/2013 | EP2608776A2 Cefpodoxime proxetil formulations |
| 07/03/2013 | EP2608775A2 Pharmaceutical composition and administrations thereof |
| 07/03/2013 | EP2608772A2 Particles for drug delivery and other applications |
| 07/03/2013 | EP2608678A1 Synbiotic product |
| 07/03/2013 | EP2608672A1 Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| 07/03/2013 | EP2608671A1 Compounds for treatment of cancer |
| 07/03/2013 | EP2608670A1 Methods for treating antipsychotic-induced weight gain |
| 07/03/2013 | EP2608669A1 NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| 07/03/2013 | EP2608668A1 Fused tricyclic inhibitors of mammalian target of rapamycin |
| 07/03/2013 | EP2608667A1 Pesticidal compositions |
| 07/03/2013 | EP2608660A2 Compositions for controlling heartworm infestation |
| 07/03/2013 | CN103189511A Method for producing novel hiPSC by means of siRNA introduction |
| 07/03/2013 | CN103189393A Method for producing and using a copolymer of sodium carboxymethyl cellulose and gossypol |
| 07/03/2013 | CN103189379A Bicyclic pyrimidines |
| 07/03/2013 | CN103189378A Pyrazolopyridinone derivatives as LPA receptor antagonists |
| 07/03/2013 | CN103189377A N1/n2-lactam acetyl-coa carboxylase inhibitors |
| 07/03/2013 | CN103189375A Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate |
| 07/03/2013 | CN103189374A Prophylactic or therapeutic agent for non-alcoholic steatohepatitis |
| 07/03/2013 | CN103189373A Substituted triazolopyridines |
| 07/03/2013 | CN103189371A Novel inhibitors of hepatitis C virus |
| 07/03/2013 | CN103189370A Triazole derivatives as ligands for GABA receptors |
| 07/03/2013 | CN103189369A Pyridinones/pyrazinones, method of making, and method of use thereof |
| 07/03/2013 | CN103189367A Chromene derivatives |
| 07/03/2013 | CN103189364A Dihydrooxazol-2-amine derivatives |
| 07/03/2013 | CN103189363A Bisaryl-bonded aryltriazolones and use thereof |
| 07/03/2013 | CN103189362A Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| 07/03/2013 | CN103189361A Estrogen receptor modulators and use thereof |
| 07/03/2013 | CN103189360A Non-hygroscopic salts of 5-HT2C agonists |
| 07/03/2013 | CN103189359A Salts of lorcaserin with optically active acids |
| 07/03/2013 | CN103189358A Fast-dissolve dosage forms of 5-ht2c agonists |
| 07/03/2013 | CN103189357A Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
| 07/03/2013 | CN103189356A N-heteroaryl compounds |
| 07/03/2013 | CN103189354A Derivatives of 1,4-dihydropyridine possessing antiviral efficacy |
| 07/03/2013 | CN103189353A Hydroxamate-based inhibitors of deacetylases |
| 07/03/2013 | CN103189350A Trans-2-decenoic acid derivative and medicament containing same |
| 07/03/2013 | CN103189337A Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 07/03/2013 | CN103189108A Theobromine in combination with an expectorant or a mucolytic for use in therapy |
| 07/03/2013 | CN103189074A Methods of treating rheumatoid arthritis using IL-17 antagonists |
| 07/03/2013 | CN103189069A Treatment of neurodegenerative diseases by targeting miRNA |
| 07/03/2013 | CN103189064A Low-dose transdermal patches with high drug release |
| 07/03/2013 | CN103189063A Therapeutic compositions and methods |